A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma.

Trial Profile

A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Veliparib (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Jan 2016 Status changed from active, no longer recruiting to completed according to the results published in the Journal of Neuro-Oncology.
    • 14 May 2015 Planned End Date changed from 1 Feb 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
    • 14 May 2015 Planned primary completion date changed from 1 Feb 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top